Crescent Inks Oncology Merger With $200M In Private Funding <https://www.law360.com/capitalmarkets/articles/2253271?nl_pk=abe82add-2a33-4388-8f7e-63d76e8f5534&utm_source=newsletter&utm_medium=email&utm_campaign=capitalmarkets&utm_content=2024-10-30&read_main=1&nlsidx=0&nlaidx=12> By Al Barbarino Crescent Biopharma Inc. has agreed to take fellow cancer-focused biotech GlycoMimetics Inc. private in a deal that includes $200 million of investments from well over a dozen firms to help fund the combined company's operations through 2027, GlycoMimetics revealed Tuesday. Read full article » <https://www.law360.com/capitalmarkets/articles/2253271?nl_pk=abe82add-2a33-4388-8f7e-63d76e8f5534&utm_source=newsletter&utm_medium=email&utm_campaign=capitalmarkets&utm_content=2024-10-30&read_more=1&nlsidx=0&nlaidx=12> | Save to favorites » <https://www.law360.com/capitalmarkets/articles/2253271?nl_pk=abe82add-2a33-4388-8f7e-63d76e8f5534&utm_source=newsletter&utm_medium=email&utm_campaign=capitalmarkets&utm_content=2024-10-30&read_later=1&nlsidx=0&nlaidx=12>